Cover Image

Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population.

Saved in:
Bibliographic Details
Main Authors: Blasi, Miriam (Author) , Eichhorn, Martin E. (Author) , Christopoulos, Petros (Author) , Winter, Hauke (Author) , Heußel, Claus Peter (Author) , Herth, Felix (Author) , El-Shafie, Rami (Author) , Kriegsmann, Katharina (Author) , Kriegsmann, Mark (Author) , Stenzinger, Albrecht (Author) , Bischoff, Helge (Author) , Thomas, Michael (Author) , Kuon, Jonas (Author)
Format: Article (Journal)
Language:English
Published: 28 June 2022
In: BMC pulmonary medicine
Year: 2022, Volume: 22, Pages: 1-8
ISSN:1471-2466
DOI:10.1186/s12890-022-02043-6
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12890-022-02043-6
Get full text
Author Notes:Miriam Blasi, Martin E. Eichhorn, Petros Christopoulos, Hauke Winter, Claus Peter Heußel, Felix J. Herth, Rami El Shafie, Katharina Kriegsmann, Mark Kriegsmann, Albrecht Stenzinger, Helge Bischoff, Michael Thomas, and Jonas Kuon
Description
Summary:Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population.
Item Description:Gesehen am 18.08.2022
Physical Description:Online Resource
ISSN:1471-2466
DOI:10.1186/s12890-022-02043-6

Similar Items